Posted by Michael Wonder on 20 Dec 2023
Budesonide for the treating primary IgA nephropathy
20 December 2023 - NICE has published evidence-based recommendations on the use of budesonide (Kinpeygo) for the treatment of adults with primary immunoglobulin A nephropathy.
Budesonide is recommended as an option for the treatment of adults with primary immunoglobulin A nephropathy when there is a risk of rapid disease progression a urinary protein to creatinine ratio of 1.5 g/g or more.
